IGC - IGC progresses into Cohort 3 of early-stage study of IGC-AD1 in Alzheimer's disease

India Globalization Capital (IGC) has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol ((THC))-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. The Data and Safety Monitoring Committee reviewed the data obtained through Cohort 1 and 2, and recommended progressing to Cohort 3, which consists of administering three doses per day.For Cohort 1, the company administered one dose of IGC-AD1 per day, which further increased to two doses in Cohort 2.Participants are monitored daily for safety and certain behavioral changes.The Phase 1 trial on Alzheimer’s patients is currently anticipated to conclude between July through September 2021.IGC shares are up 4.7% premarket trading at $1.77. The stock surged ~21.6% yesterday during regular session in sympathy with FDA approval of Biogen's Alzheimer drug.

For further details see:

IGC progresses into Cohort 3 of early-stage study of IGC-AD1 in Alzheimer’s disease